Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 6/2019

01-06-2019 | Human Immunodeficiency Virus | Review

The role of the complement system in HIV infection and preeclampsia

Authors: Yazira Pillay, Jagidesa Moodley, Thajasvarie Naicker

Published in: Inflammation Research | Issue 6/2019

Login to get access

Abstract

Background

The complement system is a key component of the innate immune system that plays a vital role in host defense, maintains homeostasis and acts as a mediator of the adaptive immune response. The complement system could possibly play a role in the pathogenesis of HIV infection and preeclampsia (PE), both of which represent major causes of maternal death in South Africa.

Recent findings

The relationship between PE and HIV infection is unclear as PE represents an exaggerated immune response, while HIV infection is associated with a decline in immune activity. Although the complement system works to clear and neutralize HIV, it could also enhance the infectivity of HIV by various other mechanisms. It has been suggested that the dysregulation of the complement system is associated with the development of PE.

Conclusion

There is currently a paucity of information on the combined effect of the complement system in HIV-associated PE. This review highlights the role of the complement system in the duality of HIV infection and PE and provides new insights into this relationship whilst also elucidating potential therapeutic targets.
Literature
1.
2.
Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014;384:258–71.CrossRefPubMed
3.
4.
UNAIDS. Ending AIDS: progress towards 90-90-90 targets. Geneva: UNAIDS; 2017.
5.
Statistics South Africa. Statistical release P0302 mid-year population estimates 2018. Pretoria: Stats SA; 2018.
6.
National Committee on Confidential Enquiries into Maternal Deaths. Saving mothers 2014–2016: seventh triennial report on confidential enquiries into maternal deaths in South Africa: short report. Pretoria: National Department of Health; 2018.
7.
Moodley J, Onyangunga OA, Maharaj NR. Hypertensive disorders in primigravid black South African women: a one-year descriptive analysis. Hypertens Pregnancy. 2016;35:529–35.CrossRefPubMed
8.
Gilbert JS, Banek CT, Katz V, Babcock S, Regal JF. Complement activation in pregnancy: too much of a good thing? Hypertension. 2012;60:1114–6.CrossRefPubMed
9.
Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72:24–43.CrossRefPubMed
10.
Silasi M, Cohen B, Karumanchi SA, Rana S. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin N Am. 2010;37:239–53.CrossRef
11.
12.
Williamson RD, McCarthy C, McCarthy FP, Kenny LC. Oxidative stress in pre-eclampsia; have we been looking in the wrong place? Pregnancy Hypertens. 2017;8:1–5.CrossRefPubMed
13.
14.
Hsu P, Nanan RKH. Innate and adaptive immune interactions at the fetal-maternal interface in healthy human pregnancy and pre-eclampsia. Front Immunol. 2014;5:125.CrossRefPubMedPubMedCentral
15.
16.
Sebitloane HM, Moodley D. The impact of highly active antiretroviral therapy on obstetric conditions: a review. Eur J Obstet Gynecol Reprod Biol. 2017;210:126–31.CrossRefPubMed
17.
Alqudah MAY, Yaseen MMM, Yaseen MMS. HIV-1 strategies to overcome the immune system by evading and invading innate immune system. HIV AIDS Rev. 2016;15:1–12.CrossRef
18.
Denny KJ, Woodruff TM, Taylor SM, Callaway LK. Complement in pregnancy: a delicate balance. Am J Reprod Immunol. 2013;69:3–11.CrossRefPubMed
19.
20.
21.
Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I—molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.PubMedPubMedCentral
22.
23.
Lokki AI, Heikkinen-Eloranta J, Jarva H, Saisto T, Lokki M-L, Laivuori H, et al. Complement activation and regulation in preeclamptic placenta. Front Immunol. 2014;5:312.CrossRefPubMedPubMedCentral
24.
25.
26.
27.
Killick J, Morisse G, Sieger D, Astier AL. Complement as a regulator of adaptive immunity. Semin Immunopathol. 2018;40:37–48.CrossRefPubMed
28.
Derzsy Z, Prohaszka Z, Rigo J Jr, Fust G, Molvarec A. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol. 2010;47:1500–6.CrossRefPubMed
29.
30.
Alrahmani L, Willrich MAV. The complement alternative pathway and preeclampsia. Curr Hypertens Rep. 2018;20:40.CrossRefPubMed
31.
Lannaman K, Romero R, Chaiworapongsa T, Kim YM, Korzeniewski SJ, Maymon E, et al. Fetal death: an extreme manifestation of maternal anti-fetal rejection. J Perinat Med. 2017;45:851–68.CrossRefPubMedPubMedCentral
32.
Richani K, Soto E, Romero R, Espinoza J, Chaiworapongsa T, Nien JK, et al. Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med. 2005;17:239–45.CrossRefPubMedPubMedCentral
33.
Albieri A, Kipnis T, Bevilacqua E. A possible role for activated complement component 3 in phagocytic activity exhibited by the mouse trophoblast. Am J Reprod Immunol. 1999;41:343–52.CrossRefPubMed
34.
Bulla R, Bossi F, Agostinis C, Radillo O, Colombo F, De Seta F, et al. Complement production by trophoblast cells at the feto-maternal interface. J Reprod Immunol. 2009;82:119–25.CrossRefPubMed
35.
36.
Madhukaran SP, Alhamlan FS, Kale K, Vatish M, Madan T, Kishore U. Role of collectins and complement protein C1q in pregnancy and parturition. Immunobiology. 2016;221:1273–88.CrossRefPubMed
37.
Singh J, Ahmed A, Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension. 2011;58:716–24.CrossRefPubMed
38.
Chow FW-N, Lee Y-L, Wong P-C, Chung M-K, Lee K-F, Shu-Biu YW. Complement 3 deficiency impairs early pregnancy in mice. Mol Reprod Dev. 2009;76:647–55.CrossRefPubMed
39.
Lokki AI, Kaartokallio T, Holmberg V, Onkamo P, Koskinen LLE, Saavalainen P, et al. Analysis of complement C3 gene reveals susceptibility to severe preeclampsia. Front Immunol. 2017;8:589.CrossRefPubMedPubMedCentral
40.
Lynch AM, Salmon JE. Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta. 2010;31:561–7.CrossRefPubMedPubMedCentral
41.
Tomimatsu T, Mimura K, Endo M, Kumasawa K, Kimura T. Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction. Hypertens Res. 2017;40:305–10.CrossRefPubMed
42.
Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol. 2010;5:173–92.CrossRefPubMed
43.
Gelber SE, Brent E, Redecha P, Perino G, Tomlinson S, Davisson RL, et al. Prevention of defective placentation and pregnancy loss by blocking innate immune pathways in a syngeneic model of placental insufficiency. J Immunol. 2015;195:1129–38.CrossRefPubMed
44.
Lillegard KE, Johnson AC, Lojovich SJ, Bauer AJ, Marsh HC, Gilbert JS, et al. Complement activation is critical for placental ischemia-induced hypertension in the rat. Mol Immunol. 2013;56:91–7.CrossRefPubMedPubMedCentral
45.
Ma Y, Kong LR, Ge Q, Lu YY, Hong MN, Zhang Y, et al. Complement 5a-mediated trophoblasts dysfunction is involved in the development of pre-eclampsia. J Cell Mol Med. 2018;22:1034–46.PubMed
46.
Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta. 2013;34:201–3.CrossRefPubMed
47.
Wu W, Yang H, Feng Y, Zhang P, Li S, Wang X, et al. Polymorphisms in complement genes and risk of preeclampsia in Taiyuan, China. Inflamm Res. 2016;65:837–45.CrossRefPubMed
48.
Mohlin FC, Gros P, Mercier E, Gris JR, Blom AM. Analysis of C3 gene variants in patients with idiopathic recurrent spontaneous pregnancy loss. Front Immunol. 2018;9:1813.CrossRefPubMedPubMedCentral
49.
Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenina L, et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 2011;8:e1001013.CrossRefPubMedPubMedCentral
50.
Lokki AI, Aalto-Viljakainen T, Meri S, Laivuori H. Genetic analysis of membrane cofactor protein (CD46) of the complement system in women with and without preeclamptic pregnancies. PLoS One. 2015;10:e0117840.CrossRefPubMedPubMedCentral
51.
52.
He Y, Xu B, Song D, Yu F, Chen Q, Zhao M. Correlations between complement system’s activation factors and anti-angiogenesis factors in plasma of patients with early/late-onset severe preeclampsia. Hypertens Pregnancy. 2016;35:499–509.CrossRefPubMed
53.
Banadakoppa M, Balakrishnan M, Yallampalli C. Upregulation and release of soluble fms-like tyrosine kinase receptor 1 mediated by complement activation in human syncytiotrophoblast cells. Am J Reprod Immunol. 2018;80:e13033.CrossRefPubMedPubMedCentral
54.
Guseh SH, Feinberg BB, Dawood HY, Yamamoto HS, Fichorova RN, Burwick RM. Urinary excretion of C5b-9 is associated with the anti-angiogenic state in severe preeclampsia. Am J Reprod Immunol. 2015;73:437–44.CrossRefPubMed
55.
Sones JL, Merriam AA, Seffens A, Brown-Grant DA, Butler SD, Zhao AM, et al. Angiogenic factor imbalance precedes complement deposition in placentae of the BPH/5 model of preeclampsia. FASEB J. 2018;32:2574–86.CrossRefPubMedPubMedCentral
56.
Lynch AM, Wagner BD, Giclas PC, West NA, Gibbs RS, Holers VM. The relationship of longitudinal levels of complement bb during pregnancy with preeclampsia. Am J Reprod Immunol. 2016;75:104–11.CrossRefPubMed
57.
Velickovic I, Dalloul M, Wong KA, Bakare O, Schweis F, Garala M, et al. Complement factor B activation in patients with preeclampsia. J Reprod Immunol. 2015;109:94–100.CrossRefPubMedPubMedCentral
58.
Hoffman MC, Rumer KK, Kramer A, Lynch AM, Winn VD. Maternal and fetal alternative complement pathway activation in early severe preeclampsia. Am J Reprod Immunol. 2014;71:55–60.CrossRefPubMed
59.
Banadakoppa M, Vidaeff AC, Yallampalli U, Ramin SM, Belfort MA, Yallampalli C. Complement split products in amniotic fluid in pregnancies subsequently developing early-onset preeclampsia. Dis Markers. 2015;2015:263109.CrossRefPubMedPubMedCentral
60.
Denny KJ, Coulthard LG, Finnell RH, Callaway LK, Taylor SM, Woodruff TM. Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia. J Reprod Immunol. 2013;97:211–6.CrossRefPubMed
61.
Burwick RM, Fichorova RN, Dawood HY, Yamamoto HS, Feinberg BB. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension. 2013;62:1040–5.CrossRefPubMed
62.
63.
64.
Sheng A, Lan J, Wu H, Lu J, Wang Y, Chu Q, et al. A clinical case–control study on the association between mannose-binding lectin and susceptibility to HIV-1 infection among northern Han Chinese population. Int J Immunogenet. 2010;37:445–54.CrossRefPubMed
65.
Tan Y, Liu L, Luo P, Wang A, Jia T, Shen X, et al. Association between mannose-binding lectin and HIV infection and progression in a Chinese population. Mol Immunol. 2009;47:632–8.CrossRefPubMed
66.
Li H, Fu WP, Hong ZH. Replication study in Chinese Han population and meta-analysis supports association between the MBL2 gene polymorphism and HIV-1 infection. Infect Genet Evol. 2013;20:163–70.CrossRefPubMed
67.
Stoiber H, Kacani L, Speth C, Wurzner R, Dierich MP. The supportive role of complement in HIV pathogenesis. Immunol Rev. 2001;180:168–76.CrossRefPubMed
68.
Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med. 2007;262:5–25.CrossRefPubMed
69.
Hu W, Yu Q, Hu N, Byrd D, Amet T, Shikuma C, et al. A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J Immunol. 2010;184:359–68.CrossRefPubMed
70.
Ellegard R, Khalid M, Svanberg C, Holgersson H, Thoren Y, Wittgren MK, et al. Complement-opsonized HIV-1 alters cross talk between dendritic cells and natural killer (NK) cells to inhibit NK killing and to upregulate PD-1, CXCR70, and CCR70 on T cells. Front Immunol. 2018;9:899.CrossRefPubMedPubMedCentral
71.
Tjomsland V, Ellegard R, Burgener A, Mogk K, Che KF, Westmacott G, et al. Complement opsonization of HIV-1 results in a different intracellular processing pattern and enhanced MHC class I presentation by dendritic cells. Eur J Immunol. 2013;43:1470–83.CrossRefPubMedPubMedCentral
72.
Ellegard R, Crisci E, Burgener A, Sjowall C, Birse K, Westmacott G, et al. Complement opsonization of HIV-1 results in decreased antiviral and inflammatory responses in immature dendritic cells via CR3. J Immunol. 2014;193:4590–601.CrossRefPubMedPubMedCentral
73.
Mishra N, Mohata M, Aggarwal H, Chaudhary O, Das BK, Sinha S, et al. Expression of complement receptor 3 (CR3) and regulatory protein CD46 on dendritic cells of antiretroviral naive and treated HIV-1 infected individuals: correlation with immune activation status. Mol Immunol. 2018;96:83–7.CrossRefPubMed
74.
75.
Harmon AC, Cornelius DC, Amaral LM, Faulkner JL, Cunningham MW Jr, Wallace K, et al. The role of inflammation in the pathology of preeclampsia. Clin Sci. 2016;130:409–19.CrossRef
76.
Rossheim AEB, Cunningham TD, Hair PS, Shah T, Cunnion KM, Troy SB. Effects of well-controlled HIV infection on complement activation and function. J Acquir Immune Defic Syndr. 2016;73:20–6.CrossRefPubMedCentral
77.
Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol. 2013;190:3831–8.CrossRefPubMed
78.
Kacani L, Banki Z, Zwirner J, Schennach H, Bajtay Z, Erdei A, et al. C5a and C5a(desArg) enhance the susceptibility of monocyte-derived macrophages to HIV infection. J Immunol. 2001;166:3410–5.CrossRefPubMed
79.
Popko K, Gorska E, Stelmaszczyk-Emmel A, Plywaczewski R, Stoklosa A, Gorecka D, et al. Proinflammatory cytokines Il-6 and TNF-alpha and the development of inflammation in obese subjects. Eur J Med Res. 2010;15(Suppl 2):120–2.PubMedPubMedCentral
80.
Huson MAM, Wouters D, van Mierlo G, Grobusch MP, Zeerleder SS, van der Poll T. HIV coinfection enhances complement activation during sepsis. J Infect Dis. 2015;212:474–83.CrossRefPubMed
81.
Khan R, Maduray K, Moodley J, Naicker T. Activation of CD35 and CD55 in HIV associated normal and pre-eclamptic pregnant women. Eur J Obstet Gynecol Reprod Biol. 2016;204:51–6.CrossRefPubMed
82.
Zhang W, Zhou Y, Ding Y. Lnc-DC mediates the over-maturation of decidual dendritic cells and induces the increase in Th1 cells in preeclampsia. Am J Reprod Immunol. 2017;77:e12647.CrossRef
83.
Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 2002;23:445–9.CrossRefPubMed
84.
Hsu P, Santner-Nanan B, Dahlstrom JE, Fadia M, Chandra A, Peek M, et al. Altered decidual DC-SIGN + antigen-presenting cells and impaired regulatory T-cell induction in preeclampsia. Am J Pathol. 2012;181:2149–60.CrossRefPubMed
85.
Bryant AK, Fazeli PL, Letendre SL, Ellis RJ, Potter M, Burdo TH, et al. Complement component 3 is associated with metabolic comorbidities in older HIV-positive adults. AIDS Res Hum Retrovir. 2016;32:271–8.CrossRefPubMedPubMedCentral
86.
Kianpour M, Norozi S, Bahadoran P, Azadbakht L. The relationship between metabolic syndrome criteria and preeclampsia in primigravid women. Iran J Nurs Midwifery Res. 2015;20:263–8.PubMedPubMedCentral
87.
Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2011;7:Cd003510.
88.
Hall D, Gebhardt S, Theron G, Grove D. Pre-eclampsia and gestational hypertension are less common in HIV infected women. Pregnancy Hypertens. 2014;4:91–6.CrossRefPubMed
89.
Govender N, Naicker T, Moodley J. Maternal imbalance between pro-angiogenic and anti-angiogenic factors in HIV-infected women with pre-eclampsia. Cardiovasc J Afr. 2013;24(5):174–9.CrossRefPubMedPubMedCentral
90.
Wimalasundera RC, Larbalestier N, Smith JH, de Ruiter A, Mc GTSA, Hughes AD, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet. 2002;360:1152–4.CrossRefPubMed
91.
Suy A, Martinez E, Coll O, Lonca M, Palacio M, de Lazzari E, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS. 2006;20:59–66.CrossRefPubMed
92.
Sansone M, Sarno L, Saccone G, Berghella V, Maruotti GM, Migliucci A, et al. Risk of preeclampsia in human immunodeficiency virus-infected pregnant women. Obstet Gynecol. 2016;127:1027–32.CrossRefPubMed
93.
Landi B, Bezzeccheri V, Guerra B, Piemontese M, Cervi F, Cecchi L, et al. HIV infection in pregnancy and the risk of gestational hypertension and preeclampsia. World J Cardiovasc Dis. 2014;4:11.CrossRef
94.
Kalumba VMS, Moodley J, Naidoo TD. Is the prevalence of pre-eclampsia affected by HIV/AIDS? A retrospective case–control study. Cardiovasc J Afr. 2013;24:24–7.CrossRefPubMedPubMedCentral
95.
Boyajian T, Shah PS, Murphy KE. Risk of preeclampsia in HIV-positive pregnant women receiving HAART: a matched cohort study. J Obstet Gynaecol Can. 2012;34:136–41.CrossRefPubMed
96.
Adams JW, Watts DH, Phelps BR. A systematic review of the effect of HIV infection and antiretroviral therapy on the risk of pre-eclampsia. Int J Gynaecol Obstet. 2016;133:17–21.CrossRefPubMed
Metadata
Title
The role of the complement system in HIV infection and preeclampsia
Authors
Yazira Pillay
Jagidesa Moodley
Thajasvarie Naicker
Publication date
01-06-2019
Publisher
Springer International Publishing
Published in
Inflammation Research / Issue 6/2019
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-019-01240-0

Other articles of this Issue 6/2019

Inflammation Research 6/2019 Go to the issue

Original Research Paper

Chicoric acid prevents methotrexate-induced kidney injury by suppressing NF-κB/NLRP3 inflammasome activation and up-regulating Nrf2/ARE/HO-1 signaling

Short Communication

The IL-23p19/EBI3 heterodimeric cytokine termed IL-39 remains a theoretical cytokine in man

Original Research Paper

Macrophage migration inhibitory factor (MIF) controls cytokine release during respiratory syncytial virus infection in macrophages

Correction

Correction to: The IL-23p19/EBI3 heterodimeric cytokine termed IL-39 remains a theoretical cytokine in man

Original Research Paper

Pharmacological effects of TAK-828F: an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease

Review

Self-regulation of the inflammatory response by peroxisome proliferator-activated receptors

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits